Buprenorphine

Overview

Buprenorphine (Buprenex®, Simbadol®, Zorbium®) is a partial mu-opioid receptor agonist commonly used in dogs and especially in cats for the management of mild to moderate pain and as part of preanesthetic drug combinations. It is available in injectable and buccal (oral transmucosal; OTM) formulations, with additional long-acting and transdermal products labeled for use in cats.

Compared with full mu-opioid agonists (eg, morphine, hydromorphone), buprenorphine generally provides less intense analgesia but has a longer duration of action and tends to produce less sedation than many other opioids. Onset of analgesia is slower than with most pure opioid agonists, and maximal analgesic effect may not be observed for up to 30 minutes after administration.

Mechanism of Action (MOA): Buprenorphine acts as a partial agonist at mu-opioid receptors and as an antagonist at kappa receptors. It has high affinity and slow dissociation from mu receptors in the central nervous system, which contributes to its prolonged duration of effect. Analgesia is dose-related but may plateau at higher doses due to its partial agonist activity.

Because of its tight receptor binding, reversal with standard doses of naloxone may be incomplete. Buprenorphine is classified as a DEA Schedule III (C-III) controlled substance.

Indications

• Mild to moderate pain (Dogs & Cats): Commonly used for perioperative and postoperative analgesia. Often included as part of multimodal pain management protocols.
• Preanesthetic medication: Frequently combined with sedatives (eg, acepromazine, medetomidine, dexmedetomidine) as part of short-term immobilization or anesthetic drug combinations.
• Isoflurane MAC-sparing effect (Dogs): IV doses (0.01–0.1 mg/kg) reduce inhalant anesthetic requirements during anesthesia.
• Epidural analgesia (Dogs): When combined with bupivacaine, provides extended postoperative analgesia (reported up to 24 hours following orthopedic procedures).
• Peripheral nerve blocks (Dogs): In combination with bupivacaine (eg, infraorbital nerve block), may extend duration of analgesia (reported up to 48–96 hours).
• FDA-approved postoperative analgesia (Cats):
  • Simbadol® (1.8 mg/mL): Long-duration SC product labeled for postoperative pain control (up to 72 hours).
  • Zorbium® (transdermal solution): Applied in-clinic prior to surgery; provides postoperative analgesia for up to 4 days.
• Buccal/OTM administration (Cats): Practical and commonly used route for short-term postoperative analgesia, though absorption may be variable. IV or IM administration may provide more reliable analgesia than SC or OTM routes.
• Combination with NSAIDs (Dogs & Cats): Multimodal analgesia (opioid + short-term NSAID) provides superior pain control compared with buprenorphine alone.

Dosage (Reference)

Dog

Buprenorphine is used for analgesia in dogs at standard injectable doses. It may also be administered as part of combination sedation or anesthetic protocols.

Cat

Buprenorphine is commonly used in cats for perioperative and postoperative analgesia. Injectable and buccal/oral transmucosal (OTM) routes are both utilized in clinical practice.

Warnings & Precautions

Buprenorphine is a partial mu-opioid agonist with high receptor affinity and prolonged duration of action. Although generally well tolerated in dogs and cats, careful patient selection and monitoring are required due to potential respiratory, hepatic, and CNS effects.

• Respiratory depression: Although uncommon, respiratory depression may occur, particularly in patients with compromised pulmonary function or when combined with other CNS depressants.
• Hepatic impairment: Use cautiously in patients with moderate to severe hepatic dysfunction, as metabolism occurs primarily in the liver and clearance may be reduced.
• Hypothyroidism, Addison’s disease, geriatric or debilitated patients: Opioids may produce exaggerated or prolonged effects; dose reduction and close monitoring are recommended.
• Head trauma or increased intracranial pressure: Use cautiously, as opioid-induced respiratory depression may increase CO₂ levels and worsen intracranial pressure.
• Biliary tract disease: May increase bile duct pressure; use with caution in patients with biliary disorders.
• Reduced GI motility: Use cautiously in animals with diminished gastrointestinal motility.
• Scorpion envenomation: Opioids are contraindicated in animals stung by scorpions (e.g., Centruroides spp.), as they may potentiate venom effects.
• Route considerations: Standard concentration buprenorphine administered SC may result in poor absorption. Intrathecal and peridural administration are not recommended.
• Excitement or behavioral changes: Mild sedation is common; however, excitement may occur (particularly in cats). Monitor behavior after administration.
• Hyperthermia (cats): Mild postoperative hyperthermia has been reported; monitor body temperature following administration.
• Reversal limitations: Due to strong receptor binding, standard doses of naloxone may not fully reverse buprenorphine’s effects.
• Controlled substance: Buprenorphine is a DEA Schedule III (C-III) drug and must be stored and handled according to regulatory requirements.

Drug Interactions

Buprenorphine interactions are primarily related to additive CNS and respiratory depression, alterations in hepatic metabolism, or pharmacodynamic interactions with other opioids and serotonergic agents. Careful monitoring and dose adjustments may be required when combined with the following:

• Local anesthetics (e.g., bupivacaine, mepivacaine): When combined in the same syringe and administered perineurally, local anesthetic effects may be potentiated.
• Benzodiazepines (e.g., diazepam, midazolam): May increase risk of CNS, cardiovascular, and respiratory depression.
• Other CNS depressants (e.g., anesthetics, barbiturates, antihistamines, phenothiazines, tranquilizers): Additive sedation and cardiorespiratory depression may occur.
• Pure mu-opioid agonists (e.g., fentanyl, hydromorphone): Buprenorphine may antagonize some analgesic effects but may also reduce sedative and respiratory depressant effects of full agonists.
• Naloxone: Will reduce analgesia but may not fully reverse buprenorphine due to its strong receptor binding.
• Monoamine oxidase inhibitors (MAOIs; e.g., selegiline, amitraz): Possible additive CNS effects; combination not recommended in humans due to risk of serotonin syndrome.
• Serotonergic agents (e.g., fluoxetine, clomipramine, mirtazapine, trazodone): Concurrent use may increase risk of serotonin syndrome.
• Tramadol: May increase risk of serotonin syndrome and respiratory depression.
• Azole antifungals (e.g., ketoconazole, itraconazole, fluconazole): May increase plasma buprenorphine concentrations.
• Erythromycin: May increase plasma buprenorphine concentrations.
• Phenobarbital or other anticonvulsants: May decrease plasma buprenorphine concentrations; additive CNS depression may also occur.
• Rifampin: May decrease plasma buprenorphine concentrations.
• Metoclopramide: May increase risk of CNS depression when used concurrently.
• Desmopressin: May increase risk of hyponatremia when used with opioids.
• QT-prolonging agents (e.g., cisapride, quinidine, sotalol): May increase risk of life-threatening arrhythmias (significance in veterinary patients unclear).

Side Effects & Overdose

Side Effects

Adverse effects of buprenorphine are generally less pronounced than with full mu-opioid agonists but may still occur, particularly with higher doses or when combined with other sedatives. Most effects are related to CNS or opioid receptor activity.

• Sedation: Most common adverse effect; degree varies between individuals.
• Respiratory depression: Rare but possible, especially in compromised patients or when combined with other CNS depressants.
• Cardiovascular effects: May cause mild decreases in heart rate and blood pressure.
• Behavioral changes (cats): Mydriasis, excessive purring, pacing, rubbing, hiding, agitation, or disorientation may occur.
• Hyperthermia (cats): Mild postoperative hyperthermia has been reported.
• Gastrointestinal effects: Vomiting, hypersalivation, or anorexia may occur; constipation has been reported.
• Dogs: Salivation, bradycardia, hypothermia, agitation, dehydration, miosis, and rarely tachycardia or hypertension may occur.
• Injection site reactions: Reported with some extended-release formulations.

Overdose

Buprenorphine has a relatively wide margin of safety; however, overdose may result in exaggerated opioid effects, particularly CNS and respiratory depression.

• Common overdose signs (dogs): Vocalization, ataxia, hypersalivation, hypothermia, and lethargy.
• Severe effects: Marked respiratory depression, bradycardia, or profound sedation.
• Treatment: Supportive care including airway management and oxygen supplementation. Naloxone may be used, but higher or repeated doses may be required due to buprenorphine’s high receptor affinity.
• Additional support: Doxapram has been suggested in cases involving significant respiratory or cardiac effects.

Key Notes

Practical clinical considerations to optimize safe and effective use of buprenorphine in dogs and cats:

• Slower onset of analgesia: Analgesic effect may not be fully established until approximately 30 minutes after administration; plan perioperative timing accordingly.
• Analgesic ceiling effect: Increasing the dose beyond recommended ranges may not proportionally increase analgesia due to partial agonist activity at the mu receptor.
• Shorter duration in some cats: Although often described as lasting 6–8 hours, clinical analgesia may be as short as 4 hours in some individuals.
• Variable response: Significant interpatient variability exists, especially with SC and buccal/OTM administration; pain scoring and reassessment are essential.
• Extended-release products: Long-acting feline formulations (e.g., high-concentration SC or transdermal products) provide prolonged analgesia but must be administered exactly as labeled.
• Multimodal approach recommended: Combining buprenorphine with NSAIDs or other analgesics typically provides superior pain control compared with opioid monotherapy.
• Controlled substance handling: Accurate documentation, secure storage, and compliance with regulatory requirements are mandatory in clinical practice.